Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T96914
(Former ID: TTDR00076)
|
|||||
| Target Name |
Plasmodium DNA gyrase (Malaria gyrase)
|
|||||
| Synonyms |
Malaria DNA gyrase subunit A
Click to Show/Hide
|
|||||
| Gene Name |
Malaria gyrase
|
|||||
| Target Type |
Successful target
|
[1] | ||||
| Disease | [+] 2 Target-related Diseases | + | ||||
| 1 | Bacterial infection [ICD-11: 1A00-1C4Z] | |||||
| 2 | Skin and skin-structure infection [ICD-11: 1F28-1G0Z] | |||||
| Function |
Essential for replication and transcription in prokaryotes. Catalyses ATP-dependent DNA supercoiling activity.
Click to Show/Hide
|
|||||
| UniProt ID | ||||||
| EC Number |
EC 5.99.1.3
|
|||||
| Sequence |
MSFKFSIVFVLYLLFLLKFNKRFIFLKSEKITSYINTQIPNYSSSPPFFLKKEAKNNIKK
CYFIKREGYRNIGTKNASNAFVLNFKSNRSTYTDNAFSCTSLCSEKKERKKVQDPYDLKA KKKEKTYELNDIKNNEKKKDDIVNASNDITNDKLDNINNNINESRKLIKGEYYDVEICEI LSKSFLSYANFLILNRCLCDYRDGLKTVQRRIIWSMYEINKGIDKKGYKKCARIVGEVIG KYHPHGDKSVYDALVRLAQKHHNNNLLIKGYGNFGSVEYNAAAMRYTEAKISSFCYDILL DEINDENVEYIKNFDGNEREPKVLCSKIPLLLINGCSGIAVSILSSIPCHNLIDVANCCI NFLINENIRDDELFHIIKGPDFSTGGIIISKYDILKNIYNSGKGNFEIRSNVFFEYIKND KKVITKHINDLSSIENSDIDKLTKKIIIKNLPPNVKPNELIENIINLLNDKKNEHDNILL RIRDESEKEDMRIVLELKKHSQIEQIHNFLSYLFKYTNMQISYHCNFVCIGYENTYTQFS LKSFIKLWCNNRIKFIKTNYEIKNKNLQKQLNIIDLYLIIQNKILDIITFFQKNQNIEQI QLYLKNNFKLNPEQIKYILSIKLQKLINIKNIDFISQRNKIMHQIKLNDEIINNVQNIKN LIIQELIYIKNKYGIHNLNKQCIIPSTPKYKYSYINSEYHPNFSKNKQIIDTYNTVSTND NNINHSNYTHDLPNTDNVTKDKNVVETNVHKNIHISSDISNNIKNSDKNSSLTKNQDSDN MMPYRNTYIDSLDNNMKDIYNNDEVLILITYGGYIKKIKINEKLKNHSNNIIKLSNVKYI LKENEEKLNENNKRLKFNDLQKGNEQEKYKDNEQKLNNDIGHNINIQNNNNDNNNNNNDN NNVLLLNEEEYNSYKIKKSILVRNRDKILLTDNYNKAFLLNVYDLHLSSYDSKGTPINQI IHSSKNITGITKFQENKKYLIVCSENGKMKVINNDVFLKRKKKGIKLFKNKKNIYFSYCN FNDNCIVGTKNGYIIQFPLSSFKISKKNSLGNKCISLAKNDKVVDLLSYENNEKNLKNYK IIFVTKNGFGKMINLNELKIQKKKGKGHRIMKFKKSKTRKDNKKDIEKKQINAINNKDKD KDIPSNNDDNNILHNTKVDEFLGFKLYDMNKQNEKDILIMITDHAVLIRKNMSLLKEKNK KHSSQIYAKMNKINQLVYFDII Click to Show/Hide
|
|||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Approved Drug(s) | [+] 1 Approved Drugs | + | ||||
| 1 | Delafloxacin Meglumine | Drug Info | Approved | Acute bacterial skin infection | [2] | |
| Mode of Action | [+] 1 Modes of Action | + | ||||
| Inhibitor | [+] 1 Inhibitor drugs | + | ||||
| 1 | Delafloxacin Meglumine | Drug Info | [1] | |||
| Different Human System Profiles of Target | Top |
|---|---|
|
Human Similarity Proteins
of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target.
A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs
(Brief Bioinform, 21: 649-662, 2020).
Human Similarity Proteins
|
|
|
There is no similarity protein (E value < 0.005) for this target
|
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. | |||||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2018 | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.